ArticleCureus2025
Epileptic Encephalopathy After Human Herpes Virus 6-Related Post-Transplant Acute Limbic Encephalitis in Children: A Case Report and Review of the Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-transplant human herpes virus 6 (HHV6) encephalitis can be followed by refractory epilepsy accompanied by intellectual decline after several months. However, such cases are extremely rare, and the disease mechanism remains elusive. We present the case of an eight-year-old boy who presented with epileptic encephalopathy 11 months after developing post-transplant acute limbic encephalitis (PALE) caused by HHV6. The patient developed multiple types of seizures, primarily characterized by epileptic spasms. Significant electroencephalographic (EEG) abnormalities were noted during the interictal period, along with regression of cognitive and language functions and progressive atrophy of the entire brain, including the hippocampus. He was managed with multiple antiepileptic drugs, although his seizures remained uncontrolled for one year after epilepsy onset. Herein, we summarized and analyzed the clinical features of the previously reported cases and the present case. The median time from the onset of HHV6 PALE to epilepsy was 11.5 months. Developmental regression or cognitive decline, multiple seizure types including tonic seizures, generalized slow waves, multifocal spike-wave activity on interictal EEG, brain changes such as hippocampal sclerosis, and poor seizure prognosis are common features. The disease was classified as epileptic encephalopathy following HHV6-related PALE (EE-PALE). This case not only provides additional evidence that EE-PALE is a distinct disease with consistent clinical features but is also expected to contribute to the identification of its pathogenesis and effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.